ViroGates A/S

DB:EP2 Stock Report

Market Cap: €13.5m

ViroGates Past Earnings Performance

Past criteria checks 0/6

ViroGates has been growing earnings at an average annual rate of 7.8%, while the Medical Equipment industry saw earnings growing at 7.5% annually. Revenues have been declining at an average rate of 3.6% per year.

Key information

7.82%

Earnings growth rate

31.37%

EPS growth rate

Medical Equipment Industry Growth4.25%
Revenue growth rate-3.61%
Return on equity-60.89%
Net Margin-113.54%
Next Earnings Update20 Aug 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ViroGates makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:EP2 Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 269-1099
31 Dec 259-1098
30 Sep 258-12108
30 Jun 259-13119
31 Mar 257-14126
31 Dec 247-14127
30 Sep 247-13127
30 Jun 247-13126
31 Mar 247-13127
31 Dec 237-12126
30 Sep 239-11127
30 Jun 2311-11129
31 Mar 2313-101210
31 Dec 2215-101311
30 Sep 2214-121410
30 Jun 2212-13168
31 Mar 229-16187
31 Dec 218-18197
30 Sep 217-18196
30 Jun 218-18196
31 Mar 217-17176
31 Dec 205-19186
30 Sep 204-21195
30 Jun 202-21195
31 Mar 203-21196
31 Dec 194-19176
30 Sep 194-16249
30 Jun 194-14227
31 Mar 194-1870
31 Dec 183-17174
30 Sep 183-1550
30 Jun 183-1450
31 Mar 182-740
31 Dec 172-630
31 Dec 164-530
31 Dec 154-440

Quality Earnings: EP2 is currently unprofitable.

Growing Profit Margin: EP2 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EP2 is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.

Accelerating Growth: Unable to compare EP2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EP2 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).


Return on Equity

High ROE: EP2 has a negative Return on Equity (-60.89%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/09 22:10
End of Day Share Price 2026/08/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ViroGates A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.